{"id":"W4386948615","doi":"10.1016/j.ygyno.2023.06.508","title":"Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Ovarian cancer; Internal medicine; Germline; Cancer; Gene; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00142736,0.0007101498,0.001193739,0.0002623901,0.0002386086,0.001007619,0.0005232243,0.0007542853,0.002904603],"category_scores_gemma":[0.001031662,0.0002660293,0.001608643,0.0002399828,0.0005760303,0.0007196259,0.0003905037,0.002650063,0.0004319062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006939681,"about_ca_system_score_gemma":0.0008862469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006433422,"about_ca_topic_score_gemma":0.002709449,"domain_scores_codex":[0.9996804,0.0001494016,0.00001437578,0.00004691335,0.00002952426,0.00007931868],"domain_scores_gemma":[0.9995255,0.00008975431,0.0001005389,0.00004426168,0.00002147618,0.0002184047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7554575,0.01278851,0.01181386,0.0008723223,0.002418742,0.0002291875,0.0002032628,0.006177134,0.02172145,0.0005351067,0.005619364,0.1821635],"study_design_scores_gemma":[0.4958989,0.4187866,0.0572617,0.0001746411,0.002435796,0.000989034,0.0001708791,0.005540583,0.008047394,0.001473371,0.009125458,0.00009552184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992566,0.003236907,0.0003318329,0.0004419836,0.0001106392,0.0002937296,0.001259782,0.00004352489,0.001715735],"genre_scores_gemma":[0.9875271,0.002237375,0.001012217,0.0006961451,0.0001011813,0.0004789119,0.003867418,0.00003739425,0.004042328],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002904603,"threshold_uncertainty_score":0.009716809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07166682431699495,"score_gpt":0.3849911861315105,"score_spread":0.3133243618145156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}